Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors

References

• TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, Blood Institute, Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014;371:22-31
   PubMed Web of Science ®Google Scholar
• Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014;371:32-41
   PubMed Web of Science ®Google Scholar
• Namboodiri KK, Kaplan EB, Heuch I, et al. The Collaborative Lipid Research Clinics Family Study: biological and cultural determinants of familial resemblance for plasma lipids and lipoproteins. Genet Epidemiol 1985;2:227-54
   PubMedGoogle Scholar
• Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008;322:1702-5
   PubMed Web of Science ®Google Scholar
• Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013;45:1345-52
   PubMed Web of Science ®Google Scholar
• Thomsen M, Varbo A, Tybjærg-Hansen A, Nordestgaard BG. Low nonfasting triglycerides and reduced all-cause mortality: a Mendelian randomization study. Clin Chem 2014;60:737-46
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011;9:258-70
   PubMed Web of Science ®Google Scholar
• Pirillo A, Norata GD, Catapano AL. Postprandial lipemia as a cardiometabolic risk factor. Curr Med Res Opin 2014;30:1489-503
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG, Karagiannis A, et al. Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Curr Drug Targets 2009;10:320-7
   PubMed Web of Science ®Google Scholar
• Athyros VG, Kakafika AI, Wierzbicki AS, et al. Targeting triglycerides in secondary prevention: should we bother? Int J Clin Pract 2009;63:15-18
   PubMed Web of Science ®Google Scholar
• Sharrett AR, Ballantyne CM, Coady SA, et al.; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-13
   PubMed Web of Science ®Google Scholar
• Assmann G, Funke H. HDL metabolism and atherosclerosis. J Cardiovasc Pharmacol 1990;16(Suppl 9):S15-20
   Google Scholar
• Athyros VG, Kakafika A, Tziomalos K, et al. Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended? Expert Opin Investig Drugs 2008;17:445-9
   PubMed Web of Science ®Google Scholar
• HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12
   PubMed Web of Science ®Google Scholar
• Carey VJ, Bishop L, Laranjo N, et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol 2010;106:757-63
   PubMed Web of Science ®Google Scholar
• Faergeman O, Holme I, Fayyad R, et al.; Steering Committees of IDEAL and TNT Trials. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol 2009;104:459-63
   PubMed Web of Science ®Google Scholar
• Miller M, Cannon CP, Murphy SA, et al.; PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008;51:724-30
   PubMed Web of Science ®Google Scholar
• Wei J, Nelson M, Szczepaniak E, et al. Myocardial triglyceride accumulation is a possible link between left ventricular diastolic dysfunction and coronary microvascular dysfunction: a pilot study. JACC 2014;63:A1587
   Google Scholar
• Nicholls SJ, Tuzcu EM, Wolski K, et al. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. J Am Coll Cardiol 2011;57:153-9
   PubMed Web of Science ®Google Scholar
• Geng Q, Ren J, Chen H, et al. Adverse events of statin–fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2013;29:181-8
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
   PubMed Web of Science ®Google Scholar
• Reyes-Soffer G, Ngai CI, Lovato L, et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care 2013;36:422-8
   PubMed Web of Science ®Google Scholar
• Tenenbaum A, Fisman EZ. ‘If it ain’t broke, don’t fix it’: a commentary on the positive–negative results of the ACCORD Lipid study. Cardiovasc Diabetol 2010;9:24
   PubMed Web of Science ®Google Scholar
• Stefanutti C, Labbadia G, Athyros VG. Hypertriglyceridaemia, postprandial lipaemia and non-HDL cholesterol. Curr Pharm Des 2014: published on line 20 June 2014. DOI: 10.2174/1381612820666140620120130
   Google Scholar
• Lee M, Saver JL, Towfighi A, et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011;217:492-8
   PubMed Web of Science ®Google Scholar
• Mihas C, Kolovou GD, Mikhailidis DP, et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr Vasc Pharmacol 2011;9:271-80
   Google Scholar
• Mihas C, Kolovou GD, Mikhailidis DP, et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr Vasc Pharmacol 2011;9:271-80
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Mikhailidis DP, Nordestgaard BG, et al. Definition of postprandial lipaemia. Curr Vasc Pharmacol 2011;9:292-301
   PubMed Web of Science ®Google Scholar
• Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008;118:993-1001
   PubMed Web of Science ®Google Scholar
• Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008;118:2047-56
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308
   PubMed Web of Science ®Google Scholar
• Langsted A, Freiberg JJ, Tybjaerg-Hansen A, et al. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 2011;270:65-75
   PubMed Web of Science ®Google Scholar
• Ridker PM. Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test? Clin Chem 2008;54:11-13
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al.; GREACE Collaborative Group. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2004;20:627-37
   PubMed Web of Science ®Google Scholar
• Athyros VG, Kakafika AI, Papageorgiou AA, et al. Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. Curr Med Res Opin 2008;24:1593-9
   PubMed Web of Science ®Google Scholar
• Nikolic D, Nikfar S, Salari P, et al.; Lipid and Blood Pressure Meta-Analysis Collaboration Group. Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2013;29:435-51
   PubMed Web of Science ®Google Scholar
• Athyros VG, Kakafika AI, Papageorgiou AA, et al.; GREACE Study Collaborative Group. Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. Lipids 2007;42:999-1009
   PubMed Web of Science ®Google Scholar
• van Wijk JP, Halkes CJ, Erkelens DW, Castro Cabezas M. Fasting and daylong triglycerides in obesity with and without type 2 diabetes. Metabolism 2003;52:1043-9
   PubMed Web of Science ®Google Scholar